Blood Cancer Trials May Use Minimal Residual Disease Measures as Endpoints, Guidance Says

Trials for hematologic malignancies can use measures of minimal residual disease (MRD) as a biomarker, according to a final guidance issued by the FDA that specifies the types and uses of measures the agency will accept.
Source: Drug Industry Daily